Home > Listed Companies Info. > Main Board Companies

:::

:::Listed Companies > Listed Companies Info. > Main Board Companies > Listed Company Profile

General Stock Board Listed Company Profile

Code:

Industry:

Local/Foreign Company:

6535 LUMOSA

中文

Company Profile

Chairman

CEO

Spokesperson

Tel

Address

Date of Listing (Regular)

Lin,Jung Chin

Charlene Yang

02-2655-7918

4F, NO. 3-2, PARK ST., NANGANG DIST.,TAIPEI CITY, TAIWAN

2016/09/26

Industry

Main Business

Biotechnology and Medical Care

Lumosa Therapeutics is dedicated to the development of innovative new drugs for the treatment of unmet medical needs in the fields of CNS and inflammatory diseases. The company is also actively engaged in scientific licensing and collaboration of first-in-class drug development. Lumosa has an experienced and well-integrated R&D and Business Development team; consist of professionals in chemical development, CMC, preclinical development, translational research, clinical development, regulatory affairs and project management, as well as intellectual property and business development.

Shr. Vol.	Highest	Lowest	Closed	Change	Transaction	TurnOver(%)	long margin balance (1,000shr.)	Short margin balance (1,000shr.)
Market Information ( 2023/06/05 )
1505.515	65.80	63.50	63.70	0.30	1158		N/A	N/A
Trading method	Fun purchase price or securities pneeded on T day	Announcement of Irregularity (2023/06/05)	TPEx measures adopted (2023/06/05)		With warrants	Can be shorted or margined?	Detail
Normal	N	N	N		N	N	Today	History

Financial Reports
Cash Flows	Items
	Items	Amount (NT$ thousand)
	Cash flows from operating activities
	Cash flows from investing activities
	Cash flows from financing activities
Balance Sheets	Current assets
	Non-current assets
	Total assets
	Current liabilities
	Non-current liabilities
	Total liabilities
	Share capital
	Capital surplus
	Retained earnings
	Other equity interest
	Treasury shares
	Total equity attributable to owners of parent
	Non-controlling interests
	Total equity
	Book Value per share(NT$)
Comprehensive Income	Operating revenue
	Operating costs
	Gross profit from operations
	Operating expenses
	Net other income (expenses)
	Net operating income
	Non-operating income and expenses
	Profit before tax
	Tax expense
	Profit from continuing operations
	Profit from discontinued operations
	Profit
	Other comprehensive income
	Comprehensive income
	Basic earnings per share

Auditor's report on latest financial statements： auditor's report：

More detail:MOPS。

Foreign issuers’ information is disclosed in consolidated statements.

TOP

TPEx

Listed Companies

General Stock Board Listed Company Profile